CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Lineage Cell Therapeutics, Inc. (AMEX: LCTX) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At ...
Lineage Cell Therapeutics (NYSE:LCTX) is scheduled to announce Q4 earnings results on Thursday, March 9th, after market close. The consensus EPS Estimate is -$0.04 (vs. -$0.17 last year) and the ...
Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback